#OncolyticViruses show potent tumor killing with minimal toxicity, and combining them with #immunotherapies like checkpoint inhibitors, CAR-T, #vaccines, #cytokines, and #BispecificTcellEngagers enhances efficacy, offering strategies for #cancer.
Read: doi.org/10.1016/j.ge...
Read: doi.org/10.1016/j.ge...
May 11, 2026 at 5:05 PM
#OncolyticViruses show potent tumor killing with minimal toxicity, and combining them with #immunotherapies like checkpoint inhibitors, CAR-T, #vaccines, #cytokines, and #BispecificTcellEngagers enhances efficacy, offering strategies for #cancer.
Read: doi.org/10.1016/j.ge...
Read: doi.org/10.1016/j.ge...
A modular albumin-based #BispecificTcellEngagers platform uses SpyCatcher/SpyTag for rapid tumor targeting, extended half-life, dose-dependent cytotoxicity, and stronger suppression than #Cetuximab in #BreastCancerModels.
#OpenAccess in #STTT: doi.org/10.1038/s413...
#OpenAccess in #STTT: doi.org/10.1038/s413...
February 27, 2026 at 11:15 AM
A modular albumin-based #BispecificTcellEngagers platform uses SpyCatcher/SpyTag for rapid tumor targeting, extended half-life, dose-dependent cytotoxicity, and stronger suppression than #Cetuximab in #BreastCancerModels.
#OpenAccess in #STTT: doi.org/10.1038/s413...
#OpenAccess in #STTT: doi.org/10.1038/s413...
Researchers identify #hypoxia-driven #VEGF secretion & EMT as key resistance mechanisms to MUC16-targeted #BispecificTcellEngagers in #OvarianCancer, with VEGF inhibition restoring T-cell cytotoxicity and immunotherapy response. @harvardmed.bsky.social
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
December 23, 2025 at 3:30 PM
Researchers identify #hypoxia-driven #VEGF secretion & EMT as key resistance mechanisms to MUC16-targeted #BispecificTcellEngagers in #OvarianCancer, with VEGF inhibition restoring T-cell cytotoxicity and immunotherapy response. @harvardmed.bsky.social
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...